Topics

Wet Macular Degeneration Pricing Market Access and Landscape 2063 [Published by First View Insight] Prices from USD $2125

21:02 EST 31 Jan 2020 | BioPortfolio Reports

Firstview Insight's Wet Macular Degeneration Pricing Market Access and Landscape 2063 provides country specific insights in order to estimate market potential for Wet Macular Degeneration based on the pricing and reimbursement scenario and perceived value drivers in different market archetypes. It gives a detailed picture of the disease landscape and unmet needs of different stakeholders existing in the current treatment paradigmThus it enables to identify and leverage on the commercial opportunities spanning across different lines of therapy. The report incorporates detailed analysis of the market development drivers as well as the preventing factors. The scope of the report covers an extensive estimation pertaining to the winning essentials and participant schemes through a presentation of the segmentation of market in the Pricing Market Access landscape.

Wet macular degeneration is a chronic eye disorder that causes blurred vision or a blind spot in your visual field. It's generally caused by abnormal blood vessels that leak fluid or blood into the macula MAKuluh. The macula is in the part of the retina responsible for central vision. Wet macular degeneration is one of two types of agerelated macular degeneration. The other type dry macular degeneration is more common and less severe. The wet type always begins as the dry type. Early detection and treatment of wet macular degeneration may help reduce vision loss and, in some instances, recover vision.

Scope of the Report:

Market Access strategy for different payer archetypes

Segmentation and mapping of payers to different archetypes based on their specific criteria of assessment i.e. costeffectiveness, budget impact, clinical effectiveness. This would enable designing effective market strategy for reimbursement in these markets. It also covers the reimbursement decisions and benefit ratings of competitor drugs by different health technology assessment bodies in EU5,US and Japan.


Payer Policy changes and implications

Provides an overview of the changing payer preferences, concerns and evolving requirements. Informs about the payer policies impacting the prescription and uptake of particular product. Estimates the future payer environment and drivers of change.


Innovative pricing and funding mechanisms

With increasing pressure from payers and limitations in evidence development, many innovative payment mechanisms are being introduced such as outcome based reimbursement, annuity based funding etc. This section provides examples of such innovative models and feasibility of their application in a particular disease scenario.


Disease Overview

This report contains comprehensive overview of disease including disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends, as well as details about treatment algorithms and treatment guidelines


Epidemiology

This section encompasses information on the incidence and prevalence of disease in EU5, US Japan.


Existing and upcoming treatment landscape

Captures the evolution of treatment paradigm including the current and emerging drug therapies. Provides information on the clinical trial results, mechanism of action, route of administration, therapeutic positioning and regulatory milestones. It gives insight into the potential therapeutic targets for drug development.


Market Trends Unmet needs

This section of the report helps to understand the market trend and opportunities by analysing the impact of current therapies on the market, current and future unmet needs, drivers and barriers and demand of better technology. This is determined by analysing the impact of various factors such as mechanism of action, route, cost of therapy, patient segmentation, existing available treatments, compliance and need of the market, expected launch timelines, competitors, brand value and KOLs perception.

Major highlights of the report

Detailed analysis of existing and upcoming competitive landscape

HTA decisions and benefit ratings for :

NICE UK

GBA Germany

HASASMR and SMRFrance

AIFA Italy

AEMPS Spain

SMC Scotland

ICER US

Chuikyo Japan

Market archetyping and product positioning

Case studies on innovative funding models

Unmet need, major barriers and drivers across the industry:

Value story for achieving reimbursement and premium pricing in different markets

Original Article: Wet Macular Degeneration Pricing Market Access and Landscape 2063 [Published by First View Insight] Prices from USD $2125

NEXT ARTICLE

More From BioPortfolio on "Wet Macular Degeneration Pricing Market Access and Landscape 2063 [Published by First View Insight] Prices from USD $2125"

Quick Search